Supported by an unrestricted grant from Allergan, Inc.
Economic impact of primary open-angle glaucoma in Australia
Version of Record online: 9 JUN 2011
© 2011 The Authors. Clinical and Experimental Ophthalmology © 2011 Royal Australian and New Zealand College of Ophthalmologists
Clinical & Experimental Ophthalmology
Volume 39, Issue 7, pages 623–632, September/October 2011
How to Cite
Dirani, M., Crowston, J. G., Taylor, P. S., Moore, P. T., Rogers, S., Pezzullo, M. L., Keeffe, J. E. and Taylor, H. R. (2011), Economic impact of primary open-angle glaucoma in Australia. Clinical & Experimental Ophthalmology, 39: 623–632. doi: 10.1111/j.1442-9071.2011.02530.x
- Issue online: 3 OCT 2011
- Version of Record online: 9 JUN 2011
- Accepted manuscript online: 18 FEB 2011 07:12AM EST
- Received 8 September 2010; accepted 24 January 2011.
- quality of life
Background: Glaucoma is the World's leading cause of irreversible blindness, and poses serious public health and economic concerns.
Samples: Published randomized trials and population-based studies since 1985.
Methods: We report the economic impact of primary open-angle glaucoma and model the effect of changes in detection rates and management strategies.
Main Outcome Measures: The cost-effectiveness of different interventions to prevent vision loss from primary open-angle glaucoma was measured in terms of financial cost (Australian dollars) and disability-adjusted life years.
Results: The prevalence of glaucoma in Australia is expected to increase from 208 000 in 2005 to 379 000 in 2025 because of the aging population. Health system costs over the same time period are estimated to increase from $AU355 million to $AU784 million. Total costs (health system costs, indirect costs and costs of loss of well-being) will increase from $AU1.9 billion to $AU4.3 billion in Australia.
Conclusion: Primary open-angle glaucoma poses a significant economic burden, which will increase substantially by 2025. This dynamic model provides a valuable tool for ongoing policy formulation and determining the economic impact of interventions to better prevent visual impairment and blindness from glaucoma.